Clinical Trials Logo

Filter by:
NCT ID: NCT03562897 Not yet recruiting - Carcinoma Clinical Trials

Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer

Start date: September 1, 2018
Phase: Phase 2
Study type: Interventional

Our hypothesis is: the nutritional supplement Ocoxin-viusid improves the quality of life of patients, including a better tolerance to neoadjuvant chemotherapy.

NCT ID: NCT03559543 Not yet recruiting - Clinical trials for Gastrointestinal Neoplasms

Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma

Start date: June 15, 2018
Phase: Phase 2
Study type: Interventional

The research product, registered as a nutritional supplement (Ocoxin®, oral solution), manufactured by Laboratorios Catalysis S. L., comes in the form of single-dose vials of 30 ml. It will be used at a rate of 60 ml daily (1 vial every 12 hours). Our main objective is To evaluate the effect of Ocoxin®-Viusid® on the quality of life of patients with metastatic colorectal adenocarcinoma. Our hypothesis is that the administration of the nutritional supplement Ocoxin®-Viusid® it is expected to improve the quality of life and enhance tolerance to chemotherapy in at least 70% of patients.

NCT ID: NCT03549494 Not yet recruiting - Clinical trials for Head and Neck Neoplasms

Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction

Start date: September 1, 2018
Phase: Phase 2
Study type: Interventional

Our main objective is to evaluate the effect of Ocoxin-Viusid on the quality of life of patients with advanced stomach cancer and esophagogastric junction. The Ocoxin-Viusid nutritional supplement is expected to improve quality of life and tolerance to treatment with Chemotherapy.

NCT ID: NCT03549273 Not yet recruiting - Neoplasms Clinical Trials

Evaluation Glizigen® and Ocoxin®-Viusid® in High-grade Cervical Intraepithelial Lesions

Start date: September 1, 2018
Phase: Phase 2
Study type: Interventional

Phase II clinical trial, monocentric, not controlled, in patients with high grade cervical intraepithelial lesions. A total of 62 patients with a diagnosis of CIN II, III or carcinoma in situ will be included. It is expected that with the combination of natural products Glizigen® and Ocoxin®-Viusid® at least 60% of patients with treated intraepithelial lesions (IEL) have a global response (complete or partial), with elimination of the human papillomavirus and the viral load.

NCT ID: NCT03543670 Active, not recruiting - Prostate Cancer Clinical Trials

Evaluation of Oncoxin-Viusid® in Prostate Cancer

Start date: September 16, 2017
Phase: Phase 2
Study type: Interventional

A not randomized clinical survey was done in 25 pacients with histological diagnosis confirmed of a prostatic adenocarcinoma and hardy in hormonotherapy at the Calixto Garcia Hospital in Habana (2016-2018). Researches had as identifying goal the efecctiveness study of Oncoxin-Viusid® nutritional supplement as a support to convencional treatment. The patient were treated with habitual doses of Docetacel and 75 mg per day of supplement during and fiften day after the quimiotherapy. The rest of numbers and severety of adverse reactions were determined as well as its influences on life quality when this co-therapy is performed, the evaluation of progresion spare survival and the porcentage of recurrences.

NCT ID: NCT03541772 Completed - Head Cancer Neck Clinical Trials

Evaluation of Oncoxin-Viusid® in Head and Neck Cancer

Start date: January 20, 2015
Phase: Phase 2
Study type: Interventional

Nutritional supplements containing antioxidants seem to decrease toxicity associated with Radiotherapy (RT) and Chemotherapy (CT) in patients with malignant head and neck tumors. Oncoxin-Viusid® (OV) is a nutritional supplement with antioxidant, immunomodulator and antitumor effects.

NCT ID: NCT03541148 Completed - Clinical trials for Cutaneous Melanoma, Stage III

Evaluation of Oncoxin-Viusid® in Cutaneous Melanoma

Start date: September 16, 2014
Phase: Phase 2
Study type: Interventional

Malignant melanoma, responsible for 75% of deaths from skin cancer. Current therapeutic options have poor response, many adverse events and high costs. For this reason, a study with nutritional supplement Oncoxin-Viusid was carried out. According to previous studies, it has an antitumor, immunomodulatory effect and to potentiate the antiproliferative effect of standard chemotherapeutic agents in different locations and stages of cancer.

NCT ID: NCT03541005 Not yet recruiting - Clinical trials for Overweight and Obesity

Evaluation of Obex® in Overweight and Obesity

Start date: October 1, 2018
Phase: Phase 3
Study type: Interventional

- Obesity is an important and growing worldwide - Obesity is highly related to the development of metabolic syndrome, diabetes, cardiovascular diseases and cancer - Diverse adverse events have been reported with the use of antiobesity drugs. - Several articles describe the beneficial effect of several specific components of the Obex® supplement on weight loss, in the reduction of waist circumference, suppression of appetite, decrease fasting glucose levels, improvement of insulin sensitivity and β cells function. - Therefore, the administration of Obex in overweight and obese patients could be an excellent strategy to induce weight loss and ameliorate the metabolic disturbances related to obesity and overweight.

NCT ID: NCT03540407 Recruiting - Clinical trials for Cervical Carcinoma Stage III

Evaluation of Oncoxin-Viusid® in Cervical Cancer and Endometrial Adenocarcinoma.

Start date: January 7, 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of oral solution Oncoxin-Viusid in the reduction of acute toxicity of Radiotherapy (RTP) and Chemotherapy (QTP) in patients with histological diagnosis of cervical cancer and endometrial adenocarcinoma. This is a phase II, prospective, randomized and double blind clinical trial, which will include 66 patients assigned to 2 treatment arms: 33 patients will receive conventional treatment, plus a placebo of the nutritional supplement and another 33 patients will receive along with the conventional treatment the Oncoxin-Viusid nutritional supplement produced by the Catalysis Laboratories of Spain. Patients will receive oral treatment throughout the onco-specific treatment and up to 3 weeks after completion.

NCT ID: NCT03533478 Active, not recruiting - Clinical trials for Diabetic Macular Edema

Alzer® and Diamel® to Prevent Severe Diabetes Macular Edema

Start date: March 1, 2015
Phase: Phase 2
Study type: Interventional

Macular edema is the main cause of low vision in diabetics. They continue looking for new treatment alternatives. The nutritional supplement Alzer, is a powerful antioxidant that together with Diamel, a supplement that has shown efficacy in metabolic control, could be a therapeutic option. Objective: To evaluate the therapeutic efficacy of the Alzer Diamel combination in mild and moderate macular edema. Material and method: A randomized double-blind phase II clinical trial versus placebo will be conducted in 64 patients, who will be randomly assigned to two groups, one will receive Alzer + Diamel and another will receive placebo from Alzer and Diamel. All patients will undergo clinical, biochemical and ophthalmological evaluation during the study.